Comparative in vitro activities of azlocillin-cefotaxime and azlocillin-tobramycin combinations against blood and multi-drug resistant bacterial isolates.
The in vitro activities of azlocillin and cefotaxime in combination and of azlocillin and tobramycin in combination against 100 blood isolates and 50 multidrug-resistant isolates were compared. With both combinations, antibacterial spectrums were complementary. Although synergy against individual strains was infrequently observed (except for azlocillin-cefotaxime against Streptococcus faecalis and azlocillin-tobramycin against Pseudomonas aeruginosa), 97% of blood isolates and 76% of multidrug-resistant isolates were susceptible to azlocillin-cefotaxime, and 94% of blood isolates and 36% of multidrug-resistant isolates were susceptible to azlocyclin-tobramycin.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001390:Azlocillin; D001419:Bacteria / Q000187:drug effects*; D002439:Cefotaxime / Q000494:pharmacology*; D004347:Drug Interactions; D006801:Humans; D008826:Microbial Sensitivity Tests; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology*; D018805:Sepsis / Q000382:microbiology; D014031:Tobramycin / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D010406:Penicillins; D001390:Azlocillin; D002439:Cefotaxime; D014031:Tobramycin